Fuzapladib sodium (Panoquell-CA1, Ceva Santé Animale) is conditionally approved by the FDA for management of clinical signs associated with acute onset pancreatitis in dogs, administered at 0.4 mg/kg IV once daily for 3 consecutive days. All treated dogs also receive standard of care — fluid therapy, antiemetics, pain management (excluding NSAIDs), and nutritional support.FDA DailyMed An…+2

The conditional approval rests on a pilot field study requiring dogs to have a canine pancreatic lipase immunoreactivity (cPLI) concentration ≥ 400 μg/L at Day 0, confirmed by abdominal imaging to exclude gastrointestinal obstruction, foreign body, and abdominal masses, and excluding dogs with severe concurrent life-threatening illness other than acute pancreatitis. The primary outcome was change in the Modified Clinical Activity Index (MCAI) — a 7-item score evaluating activity, appetite, vomiting, cranial abdominal pain, dehydration, stool consistency, and blood in stool.FDA DailyMed An…+1

Fuzapladib-treated dogs achieved a mean MCAI reduction of -7.7 to -7.75 points from Day 0 to Day 3, compared to -5.68 to -5.7 points in the placebo group. Day 0 mean MCAI scores were 8.53 (fuzapladib) and 7.68 (placebo), confirming comparable baseline severity between groups. The difference in clinical improvement was statistically significant (p = 0.02).FDA DailyMed An…+1 No significant differences were detected between groups in any secondary variables, including cPLI, cytokines, or C-reactive protein concentrations.Journal of Vete… Fuzapladib was well tolerated, with no safety concerns identified in treated dogs.Journal of the…+1

The conditional approval status reflects that full demonstration of effectiveness is still pending; additional clinical studies are ongoing and expected to conclude within a few years of the 2024 publication date. The FDA conditional approval pathway requires only a reasonable expectation of effectiveness, not the full evidentiary standard.FDA DailyMed An…+1

Published criticism of the pivotal study raises methodological concerns, including insufficient detail on the randomization procedure, and concludes that asserting a significant and beneficial clinical impact on this patient population is premature. These authors do not dismiss fuzapladib's potential but recommend cautious interpretation of the results.Journal of Vete… A separate multi-institutional analysis found that MCAI — the primary outcome tool used in the fuzapladib trial — had a concordance index of only 0.601 for predicting prolonged hospitalization (≥ 5 days) in dogs with acute pancreatitis, indicating only moderate predictive discrimination above chance.Journal of Vete…

Clinically, fuzapladib is expected to have its greatest impact in dogs that develop severe pancreatitis, given its mechanism of blocking neutrophil extravasation into pancreatic and extrapancreatic tissues. However, reliable prediction of disease severity early in the clinical course is not currently possible, even with established scoring systems.Journal of the…

Would you like to know how to select which dogs with acute pancreatitis are most appropriate candidates for fuzapladib treatment?